Comparative Pharmacology
Head-to-head clinical analysis: SATRIC versus SEPTRA DS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SATRIC versus SEPTRA DS.
SATRIC vs SEPTRA DS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SATRIC is a combination of sulfathiazole, sulfacetamide, and sulfabenzamide, which are sulfonamide antibiotics. They competitively inhibit dihydropteroate synthase, blocking folate synthesis in susceptible bacteria.
SEPTRA DS is a combination of trimethoprim and sulfamethoxazole. Trimethoprim inhibits bacterial dihydrofolate reductase, while sulfamethoxazole inhibits dihydropteroate synthase, sequentially blocking folate synthesis and ultimately DNA synthesis in susceptible bacteria.
No standard dosing information available for SATRIC.
One DS tablet (800 mg sulfamethoxazole/160 mg trimethoprim) orally every 12 hours for 10-14 days.
None Documented
None Documented
3-5 hours in healthy adults; prolonged to 6-8 hours in renal impairment (CrCl < 30 mL/min)
Trimethoprim: 8-10 hours; sulfamethoxazole: 10-12 hours (prolonged in renal impairment, e.g., creatinine clearance <30 mL/min increases half-life to >20 hours).
Renal: 70% unchanged; fecal: 20%; biliary: 10%
Renal excretion of unchanged drugs accounts for 50-70% of trimethoprim and 20-30% of sulfamethoxazole; biliary excretion is minor (<10% total).
Category C
Category C
Antiprotozoal, Antibiotic
Antibiotic